JP2023531511A5 - - Google Patents

Info

Publication number
JP2023531511A5
JP2023531511A5 JP2022579691A JP2022579691A JP2023531511A5 JP 2023531511 A5 JP2023531511 A5 JP 2023531511A5 JP 2022579691 A JP2022579691 A JP 2022579691A JP 2022579691 A JP2022579691 A JP 2022579691A JP 2023531511 A5 JP2023531511 A5 JP 2023531511A5
Authority
JP
Japan
Prior art keywords
seq
sequence
utr
sequence number
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579691A
Other languages
English (en)
Japanese (ja)
Other versions
JP7888475B2 (ja
JP2023531511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038780 external-priority patent/WO2021262909A2/en
Publication of JP2023531511A publication Critical patent/JP2023531511A/ja
Publication of JP2023531511A5 publication Critical patent/JP2023531511A5/ja
Application granted granted Critical
Publication of JP7888475B2 publication Critical patent/JP7888475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579691A 2020-06-23 2021-06-23 半減期が延長されたmRNA治療薬を含むLNP組成物 Active JP7888475B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063042822P 2020-06-23 2020-06-23
US63/042,822 2020-06-23
US202163165094P 2021-03-23 2021-03-23
US63/165,094 2021-03-23
US202163165469P 2021-03-24 2021-03-24
US63/165,469 2021-03-24
PCT/US2021/038780 WO2021262909A2 (en) 2020-06-23 2021-06-23 Lnp compositions comprising mrna therapeutics with extended half-life

Publications (3)

Publication Number Publication Date
JP2023531511A JP2023531511A (ja) 2023-07-24
JP2023531511A5 true JP2023531511A5 (cg-RX-API-DMAC10.html) 2024-07-01
JP7888475B2 JP7888475B2 (ja) 2026-07-13

Family

ID=77155849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579691A Active JP7888475B2 (ja) 2020-06-23 2021-06-23 半減期が延長されたmRNA治療薬を含むLNP組成物

Country Status (11)

Country Link
US (1) US20230242908A1 (cg-RX-API-DMAC10.html)
EP (1) EP4168556A2 (cg-RX-API-DMAC10.html)
JP (1) JP7888475B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230042005A (cg-RX-API-DMAC10.html)
CN (1) CN116194151A (cg-RX-API-DMAC10.html)
AU (1) AU2021297248A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025991A2 (cg-RX-API-DMAC10.html)
CA (1) CA3187261A1 (cg-RX-API-DMAC10.html)
IL (1) IL299196A (cg-RX-API-DMAC10.html)
MX (1) MX2022016550A (cg-RX-API-DMAC10.html)
WO (1) WO2021262909A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183909A2 (en) * 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
TW202345870A (zh) * 2022-03-25 2023-12-01 美商現代公司 具有延長半衰期之信使核糖核酸
WO2023196399A1 (en) * 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
KR20250047490A (ko) * 2023-09-27 2025-04-04 한미약품 주식회사 변형된 폴리아데닐 서열 및 ox40l 단백질 코딩서열을 포함하는 핵산 분자
KR20250047488A (ko) * 2023-09-27 2025-04-04 한미약품 주식회사 변형된 폴리아데닐 서열을 포함하는 핵산 분자
KR20250047489A (ko) * 2023-09-27 2025-04-04 한미약품 주식회사 변형된 폴리아데닐 서열 및 p53 단백질 코딩서열을 포함하는 핵산 분자
CN117603029B (zh) * 2023-11-21 2025-12-19 江苏禾本生化有限公司 一种戊菌唑关键中间体的合成方法
WO2025255199A1 (en) * 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
WO2026038929A1 (ko) * 2024-08-16 2026-02-19 서울대학교산학협력단 Rna 안정성 또는 mrna 번역 증가용 신규 조절 엘리먼트 및 이의 용도
WO2026085234A1 (en) * 2024-10-18 2026-04-23 Modernatx, Inc. 3' untranslated region sequences for extending messenger ribonucleic acids half-life

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US5723332A (en) 1993-11-26 1998-03-03 British Technology Group Limited Translational enhancer DNA
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
JP5539962B2 (ja) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
JP2022500436A (ja) * 2018-09-13 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド
MA53615A (fr) * 2018-09-14 2021-07-21 Modernatx Inc Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
EP4087544A1 (en) * 2020-01-10 2022-11-16 ModernaTX, Inc. Methods of making tolerogenic dendritic cells
EP4096720A2 (en) * 2020-01-30 2022-12-07 ModernaTX, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
CN118369111A (zh) * 2021-12-08 2024-07-19 摩登纳特斯有限公司 单纯疱疹病毒mRNA疫苗

Similar Documents

Publication Publication Date Title
DE112021000012B4 (de) Coronavirus-Vakzine
US11241493B2 (en) Coronavirus vaccine
AU2019277361B2 (en) Messenger RNA vaccines and uses thereof
US6727355B2 (en) Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JP2024514183A (ja) エプスタイン-バーウイルスmRNAワクチン
CN115175698A (zh) 冠状病毒rna疫苗
DE202019006108U1 (de) Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
JP2023526059A5 (cg-RX-API-DMAC10.html)
CN116617382B (zh) 新型冠状病毒疫苗及其制备方法和应用
WO2023137550A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
WO2024055272A1 (zh) 能高效表达目的基因的mRNA载体系统、其构建及应用
CN116615233A (zh) 用于使生物分子在受试者中表达的系统和方法
DE202023106198U1 (de) Impfstoff auf Nukleinsäurebasis
CN120813371A (zh) 用于在衣原体病的治疗中使用的组合物
WO2023050003A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
JP2025510777A5 (cg-RX-API-DMAC10.html)
US20230084012A1 (en) Vaccine for use against coronavirus and variants thereof
KR20260042173A (ko) 알파-1 안티트립신 결핍증을 위한 치료
KR20250099770A (ko) 코로나바이러스에 대한 백신
WO2024235231A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
WO2024073848A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
WO2026030201A2 (en) Vaccine antigens and use thereof
HK40090393B (en) Novel coronavirus vaccine, preparation method and use thereof
WO2026055516A1 (en) Method for prevention and treatment of viral disease
HK40090393A (en) Novel coronavirus vaccine, preparation method and use thereof